Erdafitinib for brain tumors that came back or worsened
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study tests erdafitinib, a targeted anti-cancer medicine, for certain brain cancers that have returned or progressed after standard treatment. It may help if your tumor has a specific genetic change (FGFR-TACC fusion) that this drug is designed to attack.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have an IDH-wildtype glioma (grade 2 to 4) confirmed by tumor testing
- Your tumor must test positive for an FGFR-TACC gene fusion using approved tumor genetic testing
- Your glioma must have come back or grown after at least one prior treatment (like surgery, radiation, and/or chemotherapy)
- Have measurable tumor seen on an MRI scan before starting the study treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (retifanlimab), a targeted drug (bevacizumab), and low-dose radiation for people whose glioblastoma has come back. The goal is to see if this treatment can help shrink or slow the tumor.
This Phase 2 trial studies efinetakin alfa plus pembrolizumab for adults with recurrent glioblastoma (a fast-growing brain tumor). It aims to shrink or control the tumor and help patients live longer and better after standard treatments like surgery, radiation, and temozolomide.
This early study looks at a treatment plan (including resection/surgery and an added medicine) for glioblastoma that has come back after standard therapy. The goal is to see how well it controls tumor growth and whether it is tolerable.
This trial tests a drug called tovorafenib for children and young adults with high-grade glioma or DIPG that has a specific change in the MAPK pathway. It looks at whether this targeted therapy can help after radiation treatment.
This trial tests two targeted drugs (dabrafenib and trametinib) for children and young adults with a specific type of low-grade brain tumor that has a BRAF V600 mutation. The drugs work by blocking signals that help the tumor grow.
This trial tests a targeted therapy called erdafitinib, either alone or combined with an immunotherapy drug (cetrelimab), for people with muscle-invasive bladder cancer that has a specific FGFR gene change. It may be an option if you cannot take cisplatin chemotherapy and have not had prior treatment for this cancer.
Hear when a new Recurrent Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.